Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug combination is a multi-component regional anesthetic solution used for parasternal blocks to manage postoperative pain following cardiac surgery, specifically coronary artery bypass grafting (CABG). It consists of the local anesthetic bupivacaine, the vasoconstrictor epinephrine, and two adjuncts: the corticosteroid dexamethasone and the alpha-2 adrenergic agonist dexmedetomidine. Bupivacaine provides the primary analgesic effect by blocking voltage-gated sodium channels, thereby inhibiting nerve impulse conduction. Epinephrine is included to induce local vasoconstriction, which slows the systemic absorption of the anesthetic and prolongs its duration of action. Dexamethasone and dexmedetomidine serve as perineural adjuncts that have been shown to further extend the duration of sensory blockade and improve the quality of postoperative analgesia. This specific formulation is being evaluated in clinical trials led by the Jewish General Hospital to determine its efficacy in providing long-acting pain relief and reducing opioid consumption after sternotomy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + epinephrine + dexamethasone + dexmedetomidine.